Compare MasterCard Inc (MA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Sana Biotechnology Inc — how do they compare? MasterCard Inc trades at $563.02 (market cap $491.83B), while Sana Biotechnology Inc trades at $3.74 (market cap $1.13B). The key difference: MasterCard Inc is far larger — about 435.2× Sana Biotechnology Inc's market cap, and MasterCard Inc pays a 0.62% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MA | SANA | |
|---|---|---|
Market Cap | $491.83B | $1.13B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $5.92 |
52-Week Low | $471.55 | $2.68 |
Enterprise Value | $504.86B | $1.05B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $561.44, down 0.31% on the day, with a bullish technical signal and strong fundamentals. The stock exhibits robust revenue growth, rising from $22.2B in 2022 to $32.8B in 2025, with net income margins consistently above 45%. Recent earnings beats and a consensus price target of $660.85 reflect positive momentum, supported by institutional buying and optimistic analyst coverage.
The outlook remains favorable due to sustained profitability and strategic initiatives in digital payments, though risks include competitive disruption from emerging payment technologies and high valuation multiples. With no sell ratings from analysts and solid cash flow generation, MA presents a growth opportunity tempered by execution risks in a evolving financial landscape.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
